In the past few years considerable progress regarding the knowledge of the human genome map has been achieved. As a result, attempts to use gene therapy in patients' management are more and more often undertaken.
Introduction
With the development of science, athletes enjoy the more modern methods and pharmacological agents supporting their physical fitness, muscle strength and improving athletic skills. According to the published data, gene doping is associated with the introduction into the body of the transgene and/or recombinant protein in order to bring it to expression or to modulate the expression of an existing gene to achieve the further advantage of an athlete's physiological performance [1] [2] [3] [4] [5] [6] [7] . According to the list of prohibited substances published by WADA in 2008, gene doping has been defined as: "nontherapeutic use of cells, genes, genetic elements, with chromosomes of a human cell. Other viruses, such as adenoviruses, introduce the transgene into the cell nucleus without chromosomal integration [11] .
Viral vectors are efficient gene delivery carriers and they offer several advantages: large packaging capacity, cell-specific tropism, and/or long-term expression [12] . In some cases, however, irreversible side effects, such as unexpected endogenous virus recombination, may occur. It leads to the rapid transformation of normal cells in vitro as well as initiating tumours in vivo via amplification of the host proto-oncogene sequences in the viral genome [10] [11] [12] [13] . Additionally, viral vectors can be recognized by the host immune system, resulting in an increased immune response. This effect reduces the effectiveness of the transfection efficiency by reducing the efficiency of the subsequent transgene delivery. The most important biological properties of the viral vectors used in gene therapy, including the treatment of sports injuries, are shown in Table 1 .
Non-viral gene delivery techniques are less effective methods of introducing genetic material into human cells, though characterized by low cytotoxicity. These include physical methods, such as electroporation, "gene gun" [17] and chemical carriers using cationic liposomes, or biodegradable polymers (polyethylenimines; PEIs) [18] .
Non-viral gene delivery systems may cause an increased immune response [19] [20] .
Physical methods of gene delivery allow DNA transfer into the cell cytoplasm or nucleus, through local and reversible damage of the cell membrane. The most common physical technique is electroporation, based on the application of a high voltage electrical pulse to the cells, leading to the formation of hydrophilic pores in the cell membrane, of several nanometres in diameter [15] . Electroporation is a very effective method, and one of its strengths is the protection of cells against the introduction of undesirable substances during the transgene delivery. Nowadays, electroporation is the most frequently used method to introduce DNA into skin cells or liver cells.
Biochemical methods involve the use of chemical carriers, which form complexes with nucleic acids to neutralize their negative charge.
Such complexes are introduced into the cell by phagocytosis, and less frequently by fusion with the cell membrane. Some of the chemical carriers facilitate the release of nucleic acid into the cytoplasm from the endosome, and protect it from cellular nucleases [15] .
The main difficulty in the application of gene transfer in gene doping is to achieve a long-lasting effect, as well as monitoring the changes induced in the genome. A long-lasting effect can be achieved by multiple (repeated) gene doping applications or by the integration of a transgene into the chromosome. However, it should be emphasized that the integration of gene transfer vectors is associated with a risk of undesirable side effects, including insertional mutagenesis.
Integration of the transgene at the wrong site may lead to the development of cancerous cells [21] . 
Is gene doping already a reality?
Research on gene doping, which has been carried out mainly in animal models, but also more and more often as gene therapy in humans, has brought many successes. It was reported that injection of a plasmid with a vascular endothelial growth factor (VEGFA) gene into the muscle of patients with chronic critical limb ischaemia led to improved distal flow [22] . Injection of the peroxisome proliferatoractivated receptor-delta/beta (Ppard/β) gene into mouse zygotes improved the endurance and running capacity of mice on a treadmill, and simultaneously resulted in resistance to obesity, even in the absence of exercise and with a high-fat diet [23] . In rats, the introduction of the insulin-like growth factor-1 (Igf1) gene in a recombinant viral vector led to an increase in muscle mass and strength and to increase in endurance [24] . Transfer of the phosphoenolpyruvate carboxykinase (Pck1) gene resulted in increased activity of the transgenic mice, increased strength and speed during a race, and additionally, the mice were characterized by lower mass and fat content as compared to control mice [25] .
In other studies on animals, gene therapy was used to increase the production of growth hormone (GH). By intramuscular injection of a plasmid containing the somatoliberin (Ghrh) gene, under the control of a muscle-specific gene promoter, increased concentrations of GH and IGF-1, and improvement of anabolic and haematological parameters were achieved. Moreover, the obtained results persisted for over one year [26] .
The results of such studies are a major cause for concern over the direct threat of the spread of gene doping in competitive sports.
Another problem -which is a priority for sport organizations -is the difficulty in detecting gene doping. So far, the attempts to standardize the ideal test that could be used to detect gene doping have failed [5] [6] Gene doping makes it possible to create a "super athlete", but at the cost of breaking the rules of sporting ethics and undermining the principles of fair play in sport. It is also associated with a high risk of danger to the health of athletes. Functional protein products of those genes are related to specific increase of endurance, physical strength, redistribution of fat or increase of muscle mass. Some of them control the distribution of oxygen to the tissues, or regulate the growth and/or regeneration of muscle tissue. In addition, gene doping takes into account the genes encoding the peptides that relieve pain (e.g., endorphins and enkephalins) -they can be used as prohibited analgesics [28] .
Gene doping and its side effects

Erythropoietin (EPO)
The EPO gene encodes a glycoprotein hormone that increases the number of red blood cells and the amount of oxygen in the blood, thereby increasing the oxygen supply to the muscles [29, 43] . Recombinant EPO (rEPO) is widely used to treat anaemia caused by chronic renal disease. Erythropoietin was the first recombinant haematopoietic growth factor produced and available commercially as a recombinant protein drug [30] . Several types of rEPO are now commercially available, including: epoetin alpha (Eprex, JanssenCilag), epoetin beta (Neorecormon, Roche), and darbepoetin alfa (Nespo, Dompe`) [30] [31] . It is estimated that doping with rEPO is used by 3-7% of the best athletes of endurance sports [32] .
The Sydney 2000 Olympics marked the beginning of the use of effective methods to detect injected rEPO.
Insulin-like growth factor 1 (IGF1) and growth hormone (GH)
Potentially, gene doping using IGF1 gene transfer could provide the desired, stable and high levels of IGF1 protein. This method would be relatively safe, because the effect of its actions would be limited to the target muscles. It has been shown that overexpression of IGF1
and its protein product combined with increased resistance training induced greater muscle hypertrophy [24] . Additionally, studies have
shown that IGF1 gene transfer enabled the regeneration of skeletal muscle following injury and was more efficient than systemic administration of its protein product [33] . IGF1 expression is associated with increased muscle size and weight, thereby increasing muscle strength [2] . However, IGF1 delivery may lead to profound hypogly- IGF1 protein, also known as somatomedin C, belongs to the group of polypeptide hormones, which are essential for proper development of the fetus. In the mature organism it is involved in the regeneration of tissues, especially connective tissue, and also exhibits insulin-like activity, e.g., inducing hypoglycaemia [37] . IGF1 mediates some anabolic processes of growth hormone. One of the main functions of GH -mediated also by IGF1 -is the stimulation of body growth and body weight. GH also affects carbohydrate metabolism (stimulation of glycogenolysis and increased glucose release from the liver), fat metabolism (increased lipolysis and decreased lipogenesis) and protein metabolism (increased protein synthesis) [38] . There are only a few published reports confirming the enhancing effects of GH on muscle strength and cardiovascular and respiratory functions in trained healthy individuals [39] [40] . On the other hand, evidence of the health risks associated with the use of GH (e.g., insulin resistance, impaired glucose tolerance and limited efficiency of the cardiovascular and respiratory systems) is accumulating. GH overexpression is associated with intracranial hypertension, headache, peripheral oedema, carpal tunnel syndrome, joint and muscle pain, or cardiomegaly in trained persons [41] . However, there is anecdotal evidence that recombinant GH (rGH) is commonly abused by athletes.
Hypoxia-inducible factor-1 (HIF-1)
The Based on the animal studies and early clinical trials in humans, it is believed that HIF-1 administered as gene therapy effectively induces neovascularization in ischaemic tissues [43] [44] [45] .
Peroxisome proliferator-activated receptor (PPAR)
The family of PPARs consists of the following genes: PPARA (α),
PPARD (δ), and PPARG (γ). PPAR-α influences carbohydrate-lipid
metabolism, thus regulating homeostasis and body mass [46] .
Experiments have shown that the activation of PPARD reduces weight gain, increases skeletal muscle metabolic rate and endurance, and improves insulin sensitivity. It was further found that the increase in PPARD expression suppresses atherogenic inflammation [47] .
The results of some studies suggest that polymorphisms in exon 4 (+15 C/T) and exon 7 (+65 A/G) of the PPARD gene correlate with changes in the capacity of the cardiovascular system and the concentration of lipids and glucose in healthy subjects in response to regular exercise [48, 49] . Nuclear hormone receptor protein is associated with de novo formation of skeletal muscle fibres of type I (slow-twitch fibres) and their transformation from type II fibres (fast-twitch fibres), which determine the athlete's endurance and speed. In addition, PPARD also plays an important role in the differentiation and maturation of adipocytes. It controls the body's energy balance. Thus, this protein plays an important role in the control of body weight [50] . So far, no studies have been conducted on gene doping with PPARD in humans or in animal models.
Peroxisome proliferator-activated receptor D (PPARD) agonist (GW1516; GW501516)
Animal studies showed that administration of GW1516 for a period of five weeks to mice subjected to training increased the exercise tolerance by 60-70%, as compared to mice in the control group. It is recognized that GW1516 improves the exercise capacity of trained animals [51] . However, there are no published data on the ergogenic effects of GW1516 in healthy and trained people. GW1516 is an experimental drug that has been used in the treatment of obesity, metabolic syndrome, and type 2 diabetes in some clinical trials [52] .
This molecule is included in the WADA prohibition list and there are reports that some athletes have already been caught using such doping.
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Adenosine monophosphate analogue (AMP)-(AICAR)
It is an analogue of adenosine monophosphate (AMP), the activator of AMP-dependent kinase (AMPK). Studies have shown that activated AMPK enzyme may reduce the level of anabolic processes, including synthesis of fatty acids and proteins, and increase the level of catabolic pathways such as glycolysis and fatty acid oxidation [53] . It has been proven that after 4 weeks of AICAR administration to mice subjected to training their speed and strength increased by 20-40%. It is believed that the ergogenic effect is achieved by the mutual interaction between AICAR and training, and their effect on the activation of many genes, determining the exertion efficiency [51, 54] . So far, however, there have not been published any data on AICAR ergogenic effects in healthy and trained people. AICAR is also an experimental drug and is included in the WADA prohibition list. The method to detect this molecules in humans by anti-doping laboratories was described by Narkar et al. [51] .
Myostatin (MSTN)
The protein product of the MSTN gene belongs to the transforming growth factor β (TGF-β) superfamily, and is considered as a negative regulator of muscle growth and biogenesis [55] .
In an animal model, it has been proven that suppression of the gene leads to reduced muscle growth restriction, and thus to increased muscle mass and strength [56] . Studies have demonstrated that the introduction of small interfering RNA (siRNA) into the body may negatively regulate MSTN [57] . It has been shown that suppression of the myostatin gene or protein triggers non-physiological -in terms of the number and size of cells -development of the muscle tissue.
In some pathological conditions, the increase of muscle mass in a short period of time can promote hypertonic cardiomyopathy, subsequently resulting in a heart attack. The excessive growth of muscle mass also leads to overloading of the musculoskeletal system, increasing the susceptibility to bone and tendon injuries.
Phosphoenolpyruvate carboxykinase (PCK1, PEPCK-C)
It is a key enzyme regulating gluconeogenesis. This enzyme is considered crucial in glucose homeostasis and is involved in the Krebs cycle [46] . Studies in mice have shown that its expression is associated with increased muscle endurance in animals [25] .
So far, there are no published literature data confirming the occurrence of side effects associated with transfer of the PCK1 gene or protein used as doping.
Gene transfer as a method of strengthening the desired physical and physiological characteristics or improving the natural athlete phenotype is an attractive way to achieve success in sport for many athletes [17] . For this reason, intensive investigations on the potential use of gene doping in many sports are nowadays increasing in number. Table 2 shows the genes that could be potential targets for doping in sport and indicates the potential risk to the athlete's health in case of a possible application of this type of doping.
Methods of gene doping detection
Nowadays, the detection of gene doping is a priority for many sports organizations, because of the proven effects of its use in experimental animals and the progress achieved in over 1000 clinical trials of gene therapy in humans [3] [4] .
Scientists supported by the WADA are looking for effective methods and tests for the detection of gene doping used currently in sport.
The first developed and officially approved test to detect gene doping is a test for the presence of GW1516. It is known that GW1516 affects muscle strength and endurance, and also increases the cell's ability to burn fat [9, 52, 66] . It seems that the evaluation of the host immune response to the viral vector is also an effective approach, but it requires refinement.
There is a possibility that the tested athlete could have been infected by the virus via non-doping routes (such as viral infection or reactivation of latent viral infection by a pathogen similar to the used viral vector). Therefore the test confirming the presence of antibodies against the virus in the blood will not constitute irrefutable evidence of the use of doping. It is also possible to produce genetically engineered viral vectors which are less immunogenic, thereby minimizing a host immune response [5, 67] . Systematic and periodic testing of athletes -in order to detect the antibodies against viral vectorswould be required to monitor the level of anti-viral antibodies, which could potentially be used as a method for the detection of gene doping.
Methods of gene and proteomic profiling
Profiling methods are based on the monitoring of the secondary changes which arise as a result of gene doping. Transgene expression will lead to alterations in expression of other genes and their protein products.
Gene expression profiling assesses the expression profile of endogenous genes that may be modified following the expression of the introduced gene [5, 27, 67] . For this purpose DNA microarrays -which simultaneously compare mRNA expression patterns of thousands of genes -are used. In this method mRNA is isolated from cells of the athlete who used doping and cells from normal individuals from a control group. Then, mRNA is transcribed into cDNA, which is radioactively or fluorescently labelled. The principle of the method is based on the complementary binding of synthesized cDNA with oligonucleotides (probes) immobilized on glass or silicon plates (chips). Next, a laser is used to scan the chip to visualize the fluorescent signal given by the cDNA bound to the complementary probes.
Changes in fluorescent signal intensity reflect increase/decrease of expression of the studied genes [68] [69] .
Based on this method, there is a possibility to develop microarray chips for expression analysis of the panel of genes that can be used in gene doping. Development of such chips gives the potential of expression analysis of genes used in doping as well as genes regulated by the transgene. For example, the development of a microarray chip for the EPO gene makes it possible to monitor the modified expression of about 100 EPO-dependent genes [27] . Expression analysis of these genes -in relation to the reference gene -might be an indirect method of doping detection.
Another strategy is proteomic profiling. This technique is based on the detection of minor structural differences between the recombinant proteins -which result from the expression of transgenes -and their endogenous counterparts. Investigation of global alterations in protein biomarkers upon doping can be done using the SELDI-TOF (surface enhanced laser desorption/ionization time-of-flight mass spectrometry) method, which combines chromatography and mass spectrometry for protein profiling [21, 70] . This technique is particularly applicable to indirect identification of GH, which is used in doping, by detecting the presence of the alpha chain of haemoglobin in blood serum [71] .
Another method of protein expression profiling is searching for transgenic proteins based, among others, on differences in their glycosylation or differences in the evoked host immune response. Such research has already been applied in the case of the EPO protein [72] . 
